Department of Medicine, Institut Jules Bordet, Bruxelles, Belgium
Received 17 December 2001; revised 25 February 2002; accepted 26 March 2002
![]() |
Abstract |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
A phase II randomised trial was performed with patients with SCLC to determine if the addition of carboplatin to cisplatinetoposide might improve the response rate in second-line therapy.
Patients and methods:
Sixty-five eligible patients were randomised: 31 for CE (cisplatin 20 mg/m2 and etoposide 100 mg/m2 on days 13) and 34 for CCE (carboplatin 200 mg/m2 on day 1, cisplatin 30 mg/m2 on days 23, etoposide 100 mg/m2 on days 13).
Results:
Eighty-two per cent of these patients had an objective response to first-line therapy and, among responders, 63% had a treatment-free interval of >3 months after previous therapy. The best response rates were 29% [95% confidence interval (CI) 1345] and 47% (95% CI 3064) for CE and CCE, respectively, with median survival times of 4.3 and 7.6 months. Dose-intensity analysis revealed a significant improvement in the relative dose-intensity and etoposide absolute dose-intensity for CE. Toxicity was tolerable and comparable between the two study arms.
Conclusion:
CCE appears to be associated with a high objective response rate. The phase II randomised study design suggests that a comparison between the two regimens in a phase III trial would be interesting, but will probably be difficult to perform for reasons of accrual.
Key words: carboplatin, cisplatin, etoposide, salvage therapy, small-cell lung cancer
![]() |
Introduction |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
New drugs and administration of non-cross resistant regimens are the two approaches used to investigate salvage therapy in SCLC. With respect to non-cross resistant regimens, the combination of cisplatin and etoposide (CE), usually given after failure of a first-line regimen combining cyclophosphamide, adriamycin and vincristine (VAC or CAVi), is the most active one. It results in objective response rates of between 30% and 40% [3, 4]. The converse does not apply: VAC as second-line therapy is not that effective when given after CE [57], with successful response rates of 10%. A randomised trial has shown that salvage CE is better in terms of survival than a combination of alkylating agents including carmustine, thiotepa, vincristine and cyclophosphamide [8].
Various attempts have been made to improve the results of the CE regimen in salvage indications. Increasing the dosage of etoposide to 500 mg/m2/day on days 13 with granulocyte-colony stimulating factor (G-CSF) support has resulted in significant haematological and non haematological toxicities [9]. A randomised trial [10] has compared standard doses (cisplatin 20 mg/m2/day and etoposide 60 mg/m2/day on days 15) with higher doses (40 mg/m2/day and 100 mg/m2/day, respectively, on days 15). The trial had to be discontinued early despite an improved response rate (38% compared with 27%, respectively) because of the occurrence of a high toxic death rate (24%) in the high dose area. Another way to intensify the CE regimen is to add carboplatin, as our group has done in non-small cell lung cancer (NSCLC) patients [1113], with the aim of improving the results using an increased dose-intensity of platinum-derivatives. The objective of this study by the European Lung Cancer Working Party is to test this hypothesis in a phase II randomised design, the primary end point of which is to assess antitumoral activity (response rate) in each of the two arms.
![]() |
Patients and methods |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Eligible patients were randomised between the CE regimen (cisplatin 20 mg/m2 and etoposide 100 mg/m2 i.v. on days 13) and the CCE regimen (carboplatin 200 mg/m2 on day 1, cisplatin 30 mg/m2 on days 23 and etoposide 100 mg/m2 on days 13). Cisplatin was administered i.v. in 250 ml NaCl 3% over 15 min, with prehydration and posthydration with 1 l NaCl 0.9% (+1.5 g KCl) each and 20 mg of furosemide. Carboplatine was given i.v. in 250 ml dextrose 5%. Etoposide was administered i.v. in 250 ml dextrose 5% over 1 h, following administration of the platinum derivative.
Courses were repeated every 3 weeks in case of full haematological recovery. Tumour response was assessed after the first three courses by a complete staging. Responding patients received further chemotherapy until best response, which was assessed every three courses. Patients with no change had three further courses of treatment and for those who progressed, treatment was discontinued.
The dose-adaptation plan for drugs was the following. If WBC count was <4000/mm3 and/or platelets were <100 000/mm3 on day 21, treatment was postponed for 1 week and for a maximum of 2 weeks. If myelosuppression persisted on day 36, the treatment was discontinued as a result of excessive toxicity. If the WBC nadir was <1000/mm3 and/or the platelet nadir was <100 000/mm3, doses of carboplatin and etoposide were reduced to 75%. In the case of renal toxicity with a transient creatinine elevation between 1.5 and 3.0 mg/dl, cisplatin dosage was reduced by 50% and was stopped if the peak exceeded 3.0 mg/dl. Treatment was stopped if serum creatinine was still >1.5 mg/dl at the time of a new course administration. In case of occurrence of polyneuropathy with a World Health Organization (WHO) grade >2, or of clinically evident hearing loss, cisplatin administration was stopped.
The initial work-up consisted of: (i) a complete history and physical examination; (ii) chest X-ray and computed tomography (CT) scan; (iii) bone scintigraphy with X-rays of suspected areas; (iv) CT scan or echography of the liver and adrenals; (v) brain CT scan; (vi) blood chemistries including complete blood cell counts, electrolytes, creatinine and liver function tests; and (vii) electrocardiogram (ECG). Clinical examination, chest X-ray and blood chemistries were repeated before each course. Restaging, including all tests performed during the initial work-up, was repeated after the three first courses and then every three courses thereafter in case of further chemotherapy. After discontinuation of therapy patients were assessed with clinical examination, blood chemistries and chest X-ray every 2 months for a period of 6 months, and then every 3 months.
Patients were considered assessable for response if they had completed three courses of chemotherapy. Patients records were evaluated during regular meetings of the group by at least three independent observers. Complete response (CR) was defined as the disappearance of all signs of disease, including bronchoscopic signs, for at least 4 weeks. When any lesion remained, the response was termed minimal residual disease. In measurable disease, partial response (PR) consisted of a 50% decrease in the sum of the products of the two greatest diameters of all measurable lesions, without the appearance of new lesions or progression of any lesion. Patients with unidimensionally measurable lesions were considered to have evaluable disease. In evaluable disease, PR was defined as an estimated decrease in tumour size of at least 50%. Progression was defined as an increase of >25% of at least one measurable or evaluable lesion, or the appearance of new lesions. All other circumstances were classified as no change. Patients with early death due to disease progression before evaluation, or with toxic death due to chemotherapy or early treatment discontinuation due to severe toxicity, were considered assessable.
The duration of response was the period between the date of randomisation and the date of the first observation of relapse or disease progression. Survival was measured from randomisation. Survival curves were estimated by the KaplanMeier method. The log-rank test was used to compare survival curves, and P values (two-tailed) for testing the null hypothesis for the equality of proportions were calculated using Fishers exact tests or 2 tests. P <0.05 was considered significant.
The evaluation of chemotherapy intensity was performed by the calculation of relative dose-intensity (RDI) and absolute dose-intensity (ADI). RDI was defined, for each drug, by the ratio of the received dose divided by the scheduled dose to the actual duration of treatment divided by the scheduled duration. It was expressed as a percentage of the projected intensity. The total RDI is the mean of the RDIs of all drugs. ADI was defined as the ratio of the received dose to the actual duration of treatment: it was calculated for each drug and expressed in mg/m2/week. All the formulas have been reported previously [14].
Randomisation was stratified by centre, Karnofsky PS (<70 and 80), and disease-free interval (<3 months and >3 months). The procedure was centralised and computerised. The randomisation algorithm used the minimisation technique [15]. Treatment assignment was obtained by calling the study data manager. The European Lung Cancer Working Party central office for the study coordination and analysis (including the study coordinator, the biostatistician and the data manager) was located at the Jules Bordet Institute in Brussels.
The primary end point of the trial was objective response rate. Expecting a response rate between 20% and 30% with the CE regimen, it was decided that the trial should be able to identify CCE as an interesting regimen in the case of a true response rate >30%. Using Flemings single stage procedure [16], 43 patients had to be accrued in each arm to test the null hypothesis that the true objective rate was <15%, with a sample size sufficient to reject it when the true response rate was >30% with an 80% power and using a level of = 5% (one-sided test). Secondary end points were survival, toxicity and comparison of the two regimens. No interim analysis was performed.
![]() |
Results |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Characteristics of the eligible patients are listed in Table 1. There was no major imbalance between the two study arms. All had metastatic disease except four. The vast majority had received a combination of epirubicin, vindesine and ifosfamide according to the first-line chemotherapy protocol of the Group (82%) and obtained an objective response (71%). Most of the responders (63%) had a treatment-free interval of >3 months between the end of first-line chemotherapy and the start of the second-line chemotherapy.
|
|
|
Overall survival is shown in Figure 1. Median survival times and 1-year survival rates were 4.3 months and 18% (95% CI 4% to 32%), and 7.6 months and 19% (95% CI 5% to 33%) for the CE and CCE arms, respectively. This difference was not statistically different (P = 0.11). The survival was not significantly improved (P = 0.60) according to the treatment-free interval between the first-line and second-line treatments: median survival times and 1-year survival rates were 7.4 months and 10% for a treatment-free interval of <3 months, and 7.7 months and 26% for a treatment-free-interval of >3 months.
|
|
|
![]() |
Discussion |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
This regimen was compared with the basic cisplatinetoposide regimen administered at the same dosage as in the three-drugs arm by a phase II randomised design and, despite being higher, the response rate was not statistically significantly improved. The same is true for survival. There was also no main difference in toxicity, but a significantly reduced relative dose-intensity and etoposide absolute dose-intensity for the CCE regimen. It should be emphasised that due to the design of the study, this comparison can only be considered as exploratory and the observed better response rate and survival distribution should be tested in a phase III randomised trial to allow definitive conclusions to be drawn.
As previously reported by Huisman et al. [2], responses were mainly observed in the so-called good patients with a sensitive tumour. These are patients whose cancer has responded to first-line chemotherapy with a treatment-free interval of >3 months. When we compared these patients with those who had a shorter treatment-free interval or who did not have one at all, the response rate was significantly different, confirming previous observations. There is therefore a potential selection bias in favour of good-risk patients in trials assessing second-line chemotherapy in SCLC. As a result it is very important to have a control arm to allow comparisons, as it is very difficult to manage these potential biases when comparing the data with those in other publications. For this reason we decided to conduct a phase II randomised trial.
One of the difficulties encountered in trials testing salvage therapy in SCLC is the accrual of patients. In the present study, the majority of the patients were selected from a phase III randomised trial that assessed accelerated chemotherapy and was also conducted by our group. Among the 233 patients included in the first-line trial, 53 (23%) were accrued in the second-line protocol. It took 7 years to conduct the study, which was stopped when no more eligible patients were found as a result of subsequent first-line protocols including drugs used in the present trial, rendering patients ineligible. This accrual problem makes it very difficult to conduct a phase III trial in a cooperative group as demonstrated by the literature, in which the only large study published to date was performed on an international scale by a drug company to examine topotecan [17].
Another difficulty in accruing patients lies in the fact at the present time, etoposide with or without cisplatin (or carboplatin) is almost exclusively administered during first-line chemotherapy. In a systematic review of the randomised trials testing the presence of etoposide and/or cisplatin in first-line chemotherapy for SCLC [18], we showed by meta-analysis that survival was significantly improved when etoposide or both drugs were used.
The high response rate observed as a result of the addition of carboplatin to CE is probably explained by the increased dose-intensity in platinum derivatives. Indeed, in first-line randomised trials, no difference could be observed when CE was compared with carboplatinetoposide in a relatively small Greek study [19], but survival in another trial was improved in patients with limited disease when cisplatin was added to a carboplatin-based regimen [20]. There has been no study to date to test the addition of carboplatin to a cisplatin-based combination; this merits further investigation [21].
As we have shown in a study of patients with NSCLC [22], carboplatin should no longer be prescribed in mg/m2 but according to the estimated targeted area under the concentration versus time curve (AUC). A statistically significant increase in haematological toxicity, mainly thrombopenia, was observed with an increase in the AUC for the same dosage in mg/m2. The use of the AUC therefore allows better prediction of toxicity. This approach was not used in the present trial because it was designed before the above-mentioned analysis.
A main problem for salvage therapy in SCLC is the lack of effective treatment in refractory patients when the cisplatinetoposide regimen is used in first-line therapy. As stated in the Introduction, VAC is ineffective and should no longer be used as primary chemotherapy, and topotecan does not appear to be more effective than VAC [17]. There is thus an urgent need for new active drugs for these patients.
In conclusion, our trial shows that the addition of carboplatin to cisplatinetoposide is associated with a high response rate in SCLC when given as salvage chemotherapy. The phase II randomised design of the trial suggests that a phase III randomised study comparing CCE to CE would be of interest. However, it would be very difficult to conduct due to the low accrual of eligible patients for second-line therapy protocols in SCLC, as well as the very frequent use of etoposide and/or cisplatin in first-line regimens against this disease.
![]() |
Acknowledgements |
---|
![]() |
Footnotes |
---|
![]() |
References |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
2. Huisman C, Postmus PE, Giaccone G, Smit EF. Second-line chemotherapy and its evaluation in small cell lung cancer. Cancer Treat Rev 1999; 25: 199206.[ISI][Medline]
3. Evans WK, Osoba D, Feld R et al. Etoposide (VP-16) and cisplatin: an effective treatment for relapse in small-cell lung cancer. J Clin Oncol 1985; 3: 6571.[Abstract]
4. Evans WK, Feld R, Osoba D et al. VP-16 alone and in combination with cisplatin in previously treated patients with small cell lung cancer. Cancer 1984; 53: 14611466.[ISI][Medline]
5. Shepherd FA, Evans WK, MacCormick R et al. Cyclophosphamide, doxorubicin, and vincristine in etoposide- and cisplatin-resistant small cell lung cancer. Cancer Treat Rep 1987; 71: 941944.[ISI][Medline]
6. Sculier JP, Klastersky J, Libert P et al. Cyclophosphamide, doxorubicin and vincristine with amphotericin B in sonicated liposomes as salvage therapy for small cell lung cancer. Eur J Cancer 1990; 26: 919921.
7. Roth BJ, Johnson DH, Einhorn LH et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1992; 10: 282291.[Abstract]
8. OBryan RM, Crowley JJ, Kim PN et al. Comparison of etoposide and cisplatin with bis-chloro-ethylnitrosourea, thiotepa, vincristine, and cyclophosphamide for salvage treatment in small cell lung cancer. A Southwest Oncology Group Study. Cancer 1990; 65: 856860.[ISI][Medline]
9. Masuda N, Fukuoka M, Matsui K et al. Evaluation of high-dose etoposide combined with cisplatin for treating relapsed small cell lung cancer. Cancer 1990; 65: 26352640.[ISI][Medline]
10. Trillet-Lenoir V, Lasset C, Arpin D et al. Comparaison de deux dosages de cisplatine et étoposide dans le cancer bronchique à petites cellules en rechute. Bull Cancer 1992; 79: 11731181.[ISI][Medline]
11. Sculier JP, Klastersky J, Giner V et al. Phase II randomized trial comparing high-dose cisplatin with moderate-dose cisplatin and carboplatin in patients with advanced non-small-cell lung cancer. European Lung Cancer Working Party. J Clin Oncol 1994; 12: 353359.[Abstract]
12. Sculier JP, Paesmans M, Thiriaux J et al. Phase III randomized trial comparing cisplatin and carboplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer. European Lung Cancer Working Party. J Clin Oncol 1998; 16: 13881396.[Abstract]
13. Sculier JP, Lafitte JJ, Paesmans M et al. Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer. Br J Cancer 2000; 83: 11281135.[ISI][Medline]
14. Sculier JP, Paesmans M, Bureau G et al. Multiple-drug weekly chemotherapy versus standard combination regimen in small-cell lung cancer: a phase III randomized study conducted by the European Lung Cancer Working Party. J Clin Oncol 1993; 11: 18581865.[Abstract]
15. Freedman LS, White SJ. On the use of Pocock and Simons method for balancing treatment numbers over prognostic factors in the controlled clinical trial. Biometrics 1976; 32: 691694.[ISI][Medline]
16. Machin D, Campbell MJ. Statistical Tables for the Design of Clinical Trials. Oxford: Blackwell Scientific Publications 1987.
17. von Pawel J, Schiller JH, Shepherd FA et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999; 17: 658667.
18. Mascaux C, Paesmans M, Berghmans T et al. A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer 2000; 30: 2336.[ISI][Medline]
19. Skarlos DV, Samantas E, Kosmidis P et al. Randomized comparison of etoposidecisplatin vs. etoposidecarboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study. Ann Oncol 1994; 5: 601607.[Abstract]
20. Hirsch FR, Osterlind K, Jeppesen N et al. Superiority of high-dose platinum (cisplatin and carboplatin) compared to carboplatin alone in combination chemotherapy for small-cell lung carcinoma: a prospective randomised trial of 280 consecutive patients. Ann Oncol 2001; 12: 647653.[Abstract]
21. Berghmans T, Paesmans M, Sculier JP. The role of cisplatin in the treatment of small-cell lung cancer? Ann Oncol 2001; 12: 585586.[ISI][Medline]
22. Sculier JP, Paesmans M, Thiriaux J et al. A comparison of methods of calculation for estimating carboplatin AUC with a retrospective pharmacokinetic-pharmacodynamic analysis in patients with advanced non-small cell lung cancer. European Lung Cancer Working Party. Eur J Cancer 1999; 35: 13141319.[ISI][Medline]